Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients with Chronic Kidney Disease (CKD)

Last updated: December 22, 2024
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)

Clinical Study ID

NCT06752577
24-011356
  • Ages > 18
  • All Genders

Study Summary

The purpose of this treatment protocol is to treat an intermediate-sized population with chronic kidney disease (CKD). Protocol includes a single treatment with intravenously-delivered allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) infusion. Individuals will have subsequent follow up for safety evaluations.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m^2

  • Hemoglobin A1c of ≤9%, if diabetes mellitus present

  • Ability to give informed consent

Exclusion Criteria

  • Anemia (hemoglobin <8.5 g/dL)

  • Body weight >150 kg or BMI >50

  • Uncontrolled hypertension: sustained systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg despite maximal doses of at least 2 different classes of anti-hypertensive medications

  • Chronic hypotension history: sustained SBP <85 mmHg

  • Kidney failure requiring ongoing kidney replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation)

  • Active immunosuppression therapy (including prednisone ≥10 mg daily)

  • Kidney transplantation history

  • Solid organ transplantation history

  • Recent cardiovascular event (hospitalization for myocardial infarction, stroke, congestive heart failure (NYHA class ≥III or ejection fraction ≤30%) within 3 months or uncontrolled cardiac arrhythmias (e.g. ventricular arrhythmia, supraventricular tachycardia and bradyarrhythmia)

  • History of liver cirrhosis

  • Chronic obstructive pulmonary disease or asthma requiring daily medication

  • History of blood clotting disorder (thromboembolism; pulmonary embolism, deep venous thrombosis)

  • Pregnancy

  • Unwilling to use contraception for at least 2 months after MSC infusion if sexually active and able to become pregnant or father a child.

  • Active malignancy

  • Active infection (e.g. systemic or specific organ involvement such as pneumonia or osteomyelitis)

  • Recent COVID-19 infection within the last 1 month

  • History of hepatitis B or C (without cure), or HIV infection

  • History of allergic reaction to cellular products (i.e. blood transfusions, platelets)

  • Active tobacco use

  • Illicit drug use and excessive alcohol use

  • Presence of psychosocial issues (e.g., uncontrolled mental illness, unpredictable childcare or eldercare responsibilities, irregular/ inflexible work schedule) that may interfere with the ability to complete all study procedures

  • Patients anticipating prolonged travel or other physical restrictions that would prohibit return for scheduled study visits.

  • Inability to give informed consent

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
Phase:
Study Start date:
December 22, 2024
Estimated Completion Date:
December 31, 2031

Connect with a study center

  • Mayo Clinic

    Jacksonville, Florida 32224
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.